[
  {
    "ts": "2026-02-26T19:30:00+00:00",
    "headline": "Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specif",
    "url": "https://finance.yahoo.com/news/early-study-results-johnson-johnson-193000117.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "62da3077-d2d9-3cd4-86a2-9aa9cbba00a6",
      "content": {
        "id": "62da3077-d2d9-3cd4-86a2-9aa9cbba00a6",
        "contentType": "STORY",
        "title": "Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specif",
        "pubDate": "2026-02-26T19:30:00Z",
        "displayTime": "2026-02-26T19:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/quTqSNgiT7fKbCGSKfppRg--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FHkqospZrsXFMabwu_MWUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/early-study-results-johnson-johnson-193000117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/early-study-results-johnson-johnson-193000117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]